177 related articles for article (PubMed ID: 28350120)
1. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.
Gao Y; Liu X; Li T; Wei L; Yang A; Lu Y; Zhang J; Li L; Wang S; Yin F
Oncol Rep; 2017 May; 37(5):3084-3092. PubMed ID: 28350120
[TBL] [Abstract][Full Text] [Related]
2. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.
Yin F; Yi S; Wei L; Zhao B; Li J; Cai X; Dong C; Liu X
J Cell Biochem; 2019 Apr; 120(4):6057-6070. PubMed ID: 30335894
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.
Liu X; Zou J; Su J; Lu Y; Zhang J; Li L; Yin F
Int J Oncol; 2016 Jan; 48(1):243-52. PubMed ID: 26647723
[TBL] [Abstract][Full Text] [Related]
4. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
5. Microarray-based identification of genes associated with cancer progression and prognosis in hepatocellular carcinoma.
Yin F; Shu L; Liu X; Li T; Peng T; Nan Y; Li S; Zeng X; Qiu X
J Exp Clin Cancer Res; 2016 Aug; 35(1):127. PubMed ID: 27567667
[TBL] [Abstract][Full Text] [Related]
6. Discovery of microarray-identified genes associated with ovarian cancer progression.
Liu X; Gao Y; Zhao B; Li X; Lu Y; Zhang J; Li D; Li L; Yin F
Int J Oncol; 2015; 46(6):2467-78. PubMed ID: 25891226
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
8. Low expression of KCNN3 may affect drug resistance in ovarian cancer.
Liu X; Wei L; Zhao B; Cai X; Dong C; Yin F
Mol Med Rep; 2018 Aug; 18(2):1377-1386. PubMed ID: 29901154
[TBL] [Abstract][Full Text] [Related]
9. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
10. The prognostic values of the peroxiredoxins family in ovarian cancer.
Li S; Hu X; Ye M; Zhu X
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30104402
[No Abstract] [Full Text] [Related]
11. Establishment of a SVM classifier to predict recurrence of ovarian cancer.
Zhou J; Li L; Wang L; Li X; Xing H; Cheng L
Mol Med Rep; 2018 Oct; 18(4):3589-3598. PubMed ID: 30106117
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
13. Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality.
Hossain MA; Saiful Islam SM; Quinn JMW; Huq F; Moni MA
J Biomed Inform; 2019 Dec; 100():103313. PubMed ID: 31655274
[TBL] [Abstract][Full Text] [Related]
14. Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases.
Oliveira DVNP; Prahm KP; Christensen IJ; Hansen A; Høgdall CK; Høgdall EV
Reprod Sci; 2021 Mar; 28(3):757-765. PubMed ID: 33125686
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
Diao B; Yang P
Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
[TBL] [Abstract][Full Text] [Related]
16. A random forest classifier predicts recurrence risk in patients with ovarian cancer.
Cheng L; Li L; Wang L; Li X; Xing H; Zhou J
Mol Med Rep; 2018 Sep; 18(3):3289-3297. PubMed ID: 30066910
[TBL] [Abstract][Full Text] [Related]
17. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
Helleman J; Smid M; Jansen MP; van der Burg ME; Berns EM
Gynecol Oncol; 2010 May; 117(2):170-6. PubMed ID: 20132968
[TBL] [Abstract][Full Text] [Related]
18. Prognostic values of
Chetry M; Li S; Liu H; Hu X; Zhu X
Biosci Rep; 2018 Apr; 38(2):. PubMed ID: 29472315
[TBL] [Abstract][Full Text] [Related]
19. Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival.
Lisowska KM; Olbryt M; Student S; Kujawa KA; Cortez AJ; Simek K; Dansonka-Mieszkowska A; Rzepecka IK; Tudrej P; Kupryjańczyk J
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1239-52. PubMed ID: 27028324
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of Tweety homologue 3 predicts poor clinical outcomes in ovarian cancer.
Zhou J; Xu Y; Chen X; Chen F; Zhang J; Zhu X
J Cancer; 2021; 12(23):7147-7157. PubMed ID: 34729116
[No Abstract] [Full Text] [Related]
[Next] [New Search]
